Vericiguat attenuates high phosphate-induced vascular smooth muscle cell calcification through the PKG/VASP/NF-kB/NLRP3 pathway
Abstract Background Vascular calcification is a common pathological feature of chronic kidney disease, diabetes, and atherosclerotic cardiovascular disease and is closely associated with arterial stiffness and adverse cardiovascular outcomes. High extracellular phosphate is a major driver of vascular smooth muscle cell (VSMC) calcification, promoting osteogenic phenotypic switching, inflammatory activation, and mineral deposition. Vericiguat, an oral soluble guanylate cyclase (sGC) stimulator approved for heart failure with reduced ejection fraction, enhances cyclic guanosine monophosphate signaling and exerts anti-inflammatory and cytoprotective effects. However, its effect on high phosphate-induced vascular calcification remains unclear. Methods A7r5 cells were exposed to 10 mmol/L β-glycerophosphate (β-GP) to establish an in vitro calcification model. Vericiguat was administered at 100 µmol/L. The PKG inhibitor Rp-8-Br-PET-cGMPS was used at 10 µM to evaluate the involvement of PKG signaling. Calcification, phenotypic switching, and inflammatory signaling were assessed by Alizarin Red S staining, calcium content assay, Western blotting, and ELISA. Results High phosphate significantly increased mineral deposition and calcium content in A7r5 cells. It also decreased the contractile markers α-smooth muscle actin (α-SMA) and SM22α while increasing the osteogenic markers bone morphogenetic protein 2 (BMP2) and runt-related transcription factor 2 (RUNX2). Vericiguat markedly attenuated these changes, indicating inhibition of calcification and phenotypic switching. Mechanistically, vericiguat increased the p-VASP (Ser239)/VASP ratio and reduced the p-IkBα/IkBα ratio, suggesting activation of PKG/VASP signaling and suppression of NF-kB activity. Pharmacological inhibition of PKG partially abolished the protective effects of vericiguat on calcification and osteogenic transdifferentiation. Vericiguat also suppressed high phosphate-induced activation of the NLRP3 inflammasome, as shown by reduced expression of NLRP3, ASC, p-Caspase-1, and IL-1β, together with decreased IL-1β secretion. These anti-inflammatory effects were partially reversed by PKG inhibition. Conclusions Vericiguat attenuates high phosphate-induced VSMC calcification and inflammatory activation, at least in part through the PKG/VASP/NF-kB/NLRP3 signaling pathway. Vericiguat may represent a potential therapeutic strategy for phosphate-driven vascular calcification.
Authors
- Lixia Bu
- Shaojie Li
- Xiwang Hao
- Mingfeng Ma
- Ying Zhao
- Haifeng Li
Institutions
- Shanxi Medical University (CN)
- Shanxi Fenyang Hospital (CN)
Publication Details
- Journal
- Research Square
- Published
- 2026-11-13
- DOI
- https://doi.org/10.21203/rs.3.rs-11513531/v1
- Primary Topic
- Parathyroid Disorders and Treatments
- Type
- preprint